Congenital Ichthyosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Congenital Ichthyosis Market Outlook

Thelansis’s “Congenital Ichthyosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Ichthyosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Congenital Ichthyosis Overview

Congenital recessive ichthyoses are a heterogeneous group of disorders characterized clinically by scaling of the skin and histologically by the presence of a thickened stratum corneum. Most mutations are found in the TGM1 gene encoding transglutaminase 1, involved in forming the epidermal cornified cell envelope. ABCA12 encodes an ATP-binding cassette (ABC) transporter, involved in lipid transport, and ALOX12B, ALOXE3, and CYP4F22 code, respectively, for arachidonate 12(R)-lipoxygenase, arachidonate lipoxygenase-3, and cytochrome P450 protein, all involved in lipid metabolism. Symptoms include abnormally red, dry, and rough skin with large or fine white scales. The scales’ appearance can vary; in some forms, the scales are fine and white, while in others, the scales are dark and brown, separated by deep cracks. The skin is also irritated. The skin on the palms of the hands and the soles of the feet can be very thick. Other complications can arise from more severe cases of ichthyosis. The skin loses moisture, becoming dry, tight, and inelastic. This rigidity can make movement difficult and cause the skin to crack and fissure. Walking becomes problematic when the skin on the soles of the feet thickens, and cracking around the fingers can make even simple tasks painful.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Congenital Ichthyosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034